Only in Titles

Search results for: poly

paperclip

#32746132   2020/07/03 To Up

Material Decomposition using Spectral Propagation-based Phase-contrast X-ray Imaging.

Material decomposition in X-ray imaging uses the energy-dependence of attenuation to digitally decompose an object into specific constituent materials, generally at the cost of enhanced image noise. Propagation-based X-ray phase-contrast imaging is a developing technique that can be used to reduce image noise, in particular from weakly attenuating objects. In this paper, we combine spectral phase-contrast imaging with material decomposition to both better visualize weakly attenuating features and separate them from overlying objects in radiography. We derive an algorithm that performs both tasks simultaneously and verify it against numerical simulations and experimental measurements of ideal two-component samples composed of pure aluminum and poly(methyl methacrylate). Additionally, we showcase first imaging results of a rabbit kitten's lung. The attenuation signal of a thorax, in particular, is dominated by the strongly attenuating bones of the ribcage. Combined with the weak soft tissue signal, this makes it difficult to visualize the fine anatomical structures across the whole lung. In all cases, clean material decomposition was achieved, without residual phase-contrast effects, from which we generate an un-obstructed image of the lung, free of bones. Spectral propagation-based phase-contrast imaging has the potential to be a valuable tool, not only in future lung research, but also in other systems for which phase-contrast imaging in combination with material decomposition proves to be advantageous.
Florian Schaff, Kaye S Morgan, James A Pollock, Linda C P Croton, Stuart B Hooper, Marcus J Kitchen

2890 related Products with: Material Decomposition using Spectral Propagation-based Phase-contrast X-ray Imaging.

500 Slides 500 testsOne 96-Well Microplate Ki100tests 1060 ml 50.00 ml100 70 Slides One 96-Well Microplate Ki1 kitOne 96-Well Microplate Ki

Related Pathways

paperclip

#32745972   2020/07/22 To Up

PARP inhibitors in castration-resistant prostate cancer.

Somatic or germline mutations in genes regulating DNA damage repair have been noted in around 20% of patients with advanced prostate cancer. Poly-ADP-ribose polymerase (PARP) inhibitors have shown encouraging efficacy in prostate cancer patients with DNA repair mutations. Two PARP inhibitors, olaparib, and rucaparib have recently received FDA approval for treatment of patients with advanced castration-resistant prostate cancer (CRPC), while several trials with other PARP inhibitors are ongoing. Here, we briefly summarize the current data supporting the efficacy of PARP inhibitors in advanced CRPC.
Abhishek Tripathi, Pragathi Balakrishna, Neeraj Agarwal

2081 related Products with: PARP inhibitors in castration-resistant prostate cancer.



Related Pathways

paperclip

#32745751   2020/07/21 To Up

Per- and poly-fluoroalkyl substances (PFASs) in follicular fluid from women experiencing infertility in Australia.

Per- and poly-fluoroalkyl substances (PFASs) have been widely used and detected in human matrices. Evidence that PFAS exposure may be associated with adverse human reproductive health effects exists, however, data is limited. The use of a human matrix such as follicular fluid to determine chemical exposure, along with reproductive data will be used to investigate if there is a relationship between PFAS exposure and human fertility.
Young Ran Kim, Nicole White, Jennifer Bräunig, Soumini Vijayasarathy, Jochen F Mueller, Christine L Knox, Fiona A Harden, Rosana Pacella, Leisa-Maree L Toms

1600 related Products with: Per- and poly-fluoroalkyl substances (PFASs) in follicular fluid from women experiencing infertility in Australia.

100 μg1 Set100 μg2.50 nmolProtein100 μg10 0.1ml100ug Lyophilized

Related Pathways

paperclip

#32745564   2020/07/31 To Up

Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel.

A self-microemulsifying drug delivery system (SMEDDS) was developed to enhance Paclitaxel (PTX) solubility and membrane permeability, thus improve its bioavailability. Pre-formulation studies were performed to optimize PTX-SMEDDS formulation. Then, in vitro characteristics of the formulation were determined and PTX oral absorption was investigated in rabbits. The optimized PTX-SMEDDS showed emulsification time of 31 ± 4 sec, droplet size of 19.4 ± 0.5 nm, poly-dispersibility index of 0.35 ± 0.08, percentage transmittance after dilution of 99 ± 0.02%, zeta potential of 36.82 ± 1.8 mv, cloud point of 78 ± 0.5 ºC and infinite dilution capability. The formulation maintained its physical and chemical stability during storage at 4 ºC for three months. Oral administration of 10 mg/kg of 1.5% w/w PTX-loaded SMEDDS to rabbits increased PTX bioavailability by 4.5 fold in comparison to untreated PTX suspension. While when the rabbits received 1.5% w/w PTX-loaded SMEDDS after pretreated with 1 dose and 2 doses of cyclosporine A, PTX bioavailability increased by 4.4 and 7.8 fold, respectively. This indicates that the combined effect of the SMEDDS formulation in addition to pretreatment with P-gp and CYP3A4 inhibitor, can improve the oral bioavailability of poorly soluble and poorly permeable drugs such as PTX in rabbits.
Bashaier Mohammed Al-Kandari, Monerah H Al-Soraj, Mohsen A Hedaya

2447 related Products with: Dual Formulation and Interaction Strategies to Enhance the Oral Bioavailability of Paclitaxel.

1 Set1 module100ug500 1 Set

Related Pathways

paperclip

#32744607   2020/08/03 To Up

A Rapid LC-MS-MS Method for the Quantitation of Anti-Epileptic Drugs in Urine.

Epilepsy is a common neurological disease that requires treatment with one or more medications. Due to the poly-pharmaceutical treatments, potential side-effects and drug-drug interactions associated with these medications, therapeutic drug monitoring is important. Therapeutic drug monitoring is typically performed in blood due to established clinical ranges. While blood provides the benefit of determining clinical ranges, urine requires a less invasive collection method, which is attractive for medication monitoring. As urine does not typically have established clinical ranges, it has not become a preferred specimen for monitoring medication adherence. Thus, large urine clinical data sets are rarely published, making method development that addresses reasonable concentration ranges difficult. An initial method, developed and validated in-house utilized a universal analytical range of 50-5000 ng/mL for all antiepileptic drugs and metabolites of interest in this work, namely carbamazepine, carbamazepine-10,11-epoxide, eslicarbazepine, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, 4-hydroxyphenytoin, and topiramate. This upper limit of the analytical range was too low leading to a repeat rate of 11.59% due to concentrations greater than 5000 ng/mL. Therefore, a new, fast liquid chromatography-tandem mass spectrometry (LC-MS-MS) method with a run time under 4 minutes was developed and validated for the simultaneous quantification of the previously mentioned nine antiepileptic drugs and their metabolites. Urine samples were prepared by solid phase extraction and analyzed using a Phenomenex Phenyl-Hexyl column with an Agilent 6460 LC-MS-MS instrument system. During method development and validation, the analytical range was optimized for each drug to reduce repeat analysis due to concentrations above the linear range and for carryover. This reduced the average daily repeat rate for antiepileptic testing from 11.59% to 4.82%. After validation, this method was used to test and analyze patient specimens over the course of approximately one year. The resulting concentration data was curated to eliminate specimens that could indicate an individual was non-compliant with their therapy (i.e., positive for illicit drugs) and yielded between 20 and 1700 concentration points from the patient specimens, depending on the analyte. The resulting raw quantitative urine data set is presented as preliminary reference ranges to assist with interpreting urine drug concentrations for the nine aforementioned antiepileptic medications and metabolites.
Sheng Feng, Brandi Bridgewater, Erin C Strickland, Gregory McIntire

2530 related Products with: A Rapid LC-MS-MS Method for the Quantitation of Anti-Epileptic Drugs in Urine.

400Tests100 μg100 μg100 μg100 μg100.00 ug1 mL100 μg

Related Pathways

paperclip

#32744499   2020/08/03 To Up

Single molecule poly(A) tail-seq shows LARP4 opposes deadenylation through mRNA lifespan with most impact on short tails.

La-related protein 4 (LARP4) directly binds both poly(A) and poly(A)-binding protein (PABP). LARP4 was shown to promote poly(A) tail (PAT) lengthening and stabilization of individual mRNAs presumably by protection from deadenylation (Mattijssen et al., 2017). We developed a nucleotide resolution transcriptome-wide, single molecule SM-PAT-seq method. This revealed LARP4 effects on a wide range of PAT lengths for human mRNAs and mouse mRNAs from LARP4 knockout (KO) and control cells. LARP4 effects are clear on long PAT mRNAs but become more prominent at 30-75 nucleotides. We also analyzed time courses of PAT decay transcriptome-wide and for ~200 immune response mRNAs. This demonstrated accelerated deadenylation in KO cells on PATs <75 nucleotides and phasing features consistent with greater PABP dissociation in the absence of LARP4. Thus, LARP4 shapes PAT profiles throughout mRNA lifespan and with impact on mRNA decay at short lengths known to sensitize PABP dissociation in response to deadenylation machinery.
Sandy Mattijssen, James R Iben, Tianwei Li, Steven L Coon, Richard J Maraia

2574 related Products with: Single molecule poly(A) tail-seq shows LARP4 opposes deadenylation through mRNA lifespan with most impact on short tails.

500 mouse tails (100 ml)250 mouse tails (50 ml)1ml100 ug0.1100 µg100 Reactions100μl1 mg

Related Pathways

paperclip

#32744283   2020/08/03 To Up

A coil-to-globule transition capable coarse-grained model for poly(N-isopropylacrylamide).

We present a model for mesoscopic molecular dynamics simulations of poly(N-isopropyl-acrylamide) (pNIPAM). The model uses a coarse-grained scheme based on the explicit-solvent Martini force field. The mapping of the polymer accounts for three beads per monomer. Similarly to the Martini water bead, the amide moieties of the polymer include an electric dipole. The model is tested by building polymer chains of different sizes and proved to accurately capture the thermal response of pNIPAM without including any temperature-dependent parameters. The critical temperature of the model is observed at (302.1 ± 1.1) K for a 35-mer and it keeps invariant when increasing the chain length. We deployed a series of replica-exchange molecular dynamics simulations that evidence the oligomer reaches thermodynamic equilibrium irrespective of the starting configuration. Finally, the model is applied to a membrane structure of pNIPAM where a good agreement with previous atomistic simulations is observed.
H A Pérez-Ramírez, G Odriozola

1183 related Products with: A coil-to-globule transition capable coarse-grained model for poly(N-isopropylacrylamide).

100μl 1 G 100 G1,000 tests0.1 ml0.1 mgper vial1 g100 TESTS

Related Pathways

paperclip

#32744264   2020/08/03 To Up

Substrate-independent polymer coating with stimuli-responsive dexamethasone release for on-demand fibrosis inhibition.

Tissue fibrosis caused by implantation of tissue engineering scaffolds is an urgent problem in clinical research. In this work, a substrate-independent coating with on-demand release of an antifibrotic drug has been fabricated to effectively address this issue. This coating was formed through a substrate-independent layer-by-layer (LBL) technique via a cationic polyelectrolyte (poly-diallyldimethylammonium, PDDA) and an anionic polyelectrolyte (poly-styrenesulfonate, PSS), where parts of PSS and PDDA were physically replaced by carboxyl functionalized polyethylene glycol grafted onto antifibrotic drug dexamethasone (DEX-PEG-COOH). Considering the easy generation of local inflammation after implantation, an ester bond was designed between PEG-COOH and DEX. Therefore, the overexpressed esterase under inflammatory conditions hydrolyzes the ester bond and thereby releases DEX from the film to inhibit fibrosis occurring in the tissue repair process. The in vivo capacity of this coating to restrain tissue fibrosis was investigated by a skin defect model using porous polycaprolactone (PCL) scaffolds as substrates. The experimental results showed that the fibrosis-related proteins (Col-I, TGF-β and fibronectin) and the infiltration of myofibroblasts (α-SMA) of skin tissues in the coated PCL scaffold group were significantly lower than those in the blank control group and pure PCL scaffold group. Moreover, the histological evaluations showed that the coating group could significantly decrease the deposition of collagen and meanwhile promote the partial regeneration of skin appendages. These results successfully demonstrate that the universal coating prepared with a simple protocol would be an effective strategy to address the fibrosis issues during tissue engineering.
Pingyun Yuan, Xinyu Qiu, Tao Liu, Ran Tian, Yongkang Bai, Shiyu Liu, Xin Chen, Yan Jin

2998 related Products with: Substrate-independent polymer coating with stimuli-responsive dexamethasone release for on-demand fibrosis inhibition.

50 ml1000 assays 1 G100 tests1000 assays100ug Lyophilized10 g100ug2500 Units

Related Pathways

paperclip

#32744119   2020/08/02 To Up

Mice deficient in UXT exhibit retinitis pigmentosa-like features via aberrant autophagy activation.

UXT (ubiquitously expressed prefoldin like chaperone), a small chaperone-like protein, is widely expressed in diverse human and mouse tissues and is more abundant in retina and kidney. However, the functional characterization of UXT at tissue level was largely unknown. Here, we reported that mice deficient in UXT exhibited salient features of retinal degenerative disease, similar to retinitis pigmentosa. Conditional knockout (CKO) of led to retinal degeneration and pigmentation in mice retina along with significant alterations of retinitis pigmentosa-related genes, which indicated UXT might be associated with retinal degenerative disease sharing key features to retinitis pigmentosa. Consistently, the electroretinogram (ERG) responses were dramatically impaired in CKO retinas. Strong degenerative features were observed in CKO retinas, including specific and progressive reduction of photoreceptor cells and increased numbers of apoptotic cells. Intriguingly, macroautophagic/autophagic flux was enhanced in CKO retina. Mechanistically, we found UXT was indispensable to suppress photoreceptor apoptotic cell death by inhibiting autophagy through regulating the activity of MTOR (mechanistic target of rapamycin kinase), a key negative regulator of autophagy. Conversely, knockdown of UXT induced the robust expression of the canonical autophagy-related genes and boosted autophagic flux and apoptosis, finally resulting in severe retina degeneration in CKO mice. Taken together, our study reveals a vital role of UXT in preventing retina from degeneration. The loss of UXT results in a hyper-autophagic state leading to massive retinal degeneration. Therefore, UXT may be a crucial target for retinal degenerative disease.
Mingyu Pan, Yue Yin, Xinxia Wang, Quanyi Wang, Lele Zhang, Haiyang Hu, Chen Wang

1087 related Products with: Mice deficient in UXT exhibit retinitis pigmentosa-like features via aberrant autophagy activation.

100ug100μg100μg25 Bags/Unit100ug2 mg100 μg1 Set100 μg2ug

Related Pathways

paperclip

#32744024   // To Up

Daifan San intervenes in forkhead box P3 and the interleukin (IL)-23/IL-17A signaling pathway to help prevent and treat primary biliary cirrhosis.

To investigate the mechanism by which Daifan San (DFS) prevents and treats primary biliary cirrhosis (PBC) via the forkhead box P3 (FoxP3) and interleukin (IL)-23/IL-17A signaling pathways.
Kai Zhan, Yan Xu, Mengling Han, Liangbin Cheng

1909 related Products with: Daifan San intervenes in forkhead box P3 and the interleukin (IL)-23/IL-17A signaling pathway to help prevent and treat primary biliary cirrhosis.

5ug2 Pieces/Box2 Pieces/Box7 inhibitors2 Pieces/Box2 Pieces/Box5ug11 inhibitors5ug

Related Pathways